DX Oncotype analysis is a diagnostic assay that can help women with certain types of breast cancer to learn more about the biology of their tumor.
Along with other information, the results of the Oncotype DX can help women and their doctors to make decisions on whether to include or not chemotherapy in their treatment regimen. It can also help in evaluating the possibility of the cancer’s reappearance in the future (distant recurrence).
Oncotype DX assay analyzes a total of 21 genes of the woman’s tumor sample -16 cancer genes five reference genes- to determine how they are expressed, or how active they are. The analysis results are reported as a quantified result, called Recurrence Score®, which ranges from 0-100 and is associated with the possibility of the cancer’s recurrence and the possibility for the woman to benefit from adding chemotherapy to her hormonal treatment.
The Oncotype DX analysis provides additional information to the standard measures (such as tumor size, grade of tumor and the status of the lymph nodes) that doctors traditionally use to calculate the possibility of the cancer’s recurrence in a woman and help her get her therapeutic decisions.
Oncotype DX analysis is the only analysis of its kind established under specific conditions of the treatment guidelines of the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN) and therapeutic guidelines of St. Gallen. Oncotype DX analysis is also recognized by the European Society of Medical Oncology (ESMO) as a useful diagnostic tool to obtain additional prognostic and / or predictive information to support pathology assessment and to predict the response to adjuvant chemotherapy in patients with early breast cancer with positive estrogen receptors. Furtermore, the Panel of the International Guidelines for Breast Cancer of St. Gallen has included the Oncotype DX as a predictive marker for the Benefit of chemotherapy. These guidelines were developed by expert scientists to help doctors provide to their patients the best possible care. The Oncotype DX has been requested by more than 10,000 physicians in over 60 countries and more than 200,000 patients (until March 2011).